Targeting Purinergic Signaling and Cell Therapy in Cardiovascular and Neurodegenerative Diseases

Autor(es)

Andrejew, Roberta ; Glaser, Talita ; Oliveira-Giacomelli, Agatha ; Ribeiro, Deidiane ; Godoy, Mariana ; Granato, Alessandro ; Ulrich, Henning ; Ratajczak, MZ

• Tipo de documento: Artigo Científico
• Fonte: STEM CELLS: THERAPEUTIC APPLICATIONS; v. 1201, p. 79-pg., 2019-01-01.

Resumo

Extracellular purines exert several functions in physiological and -pathophysiological mechanisms. ATP acts through P2 receptors as a neurotransmitter and neuromodulator and modulates heart contractility, while adenosine participates in neurotransmission, blood pressure, and many other mechanisms. Because of their capability to differentiate into mature cell types, they provide a unique therapeutic strategy for regenerating damaged tissue, such as in cardiovascular and neurodegenerative diseases. Purinergic signaling is pivotal for controlling stem cell differentiation and phenotype determination. Proliferation, differentiation, and apoptosis of stem cells of various origins are regulated by purinergic receptors. In this chapter, we selected neurodegenerative and cardiovascular diseases with clinical trials using cell therapy and purinergic receptor targeting. We discuss these approaches as therapeutic alternatives to neurodegenerative and cardiovascular diseases. For instance, promising results were demonstrated in the utilization of mesenchymal stem cells and bone marrow mononuclear cells in vascular regeneration. Regarding neurodegenerative diseases, in general, P2X7 and A(2A) receptors mostly worsen the degenerative state. Stem cell-based therapy, mainly through mesenchymal and hematopoietic stem cells, showed promising results in improving symptoms caused by neurodegeneration. We propose that purinergic receptor activity regulation combined with stem cells could enhance proliferative and differentiation rates as well as cell engraftment. (AU)

• Processo FAPESP: 18/08426-0 - Alcalóides indólicos, subprodutos do processamento de Maqui (Aristotelia chilensis) como aditivos alimentares no tratamento da Doença de Alzheimer
• Beneficiário: Alexander Henning Ulrich
• Modalidade de apoio: Auxílio à Pesquisa - Regular
• Processo FAPESP: 19/05384-8 - Papel da Bradicinina na Metástase de Neuroblastoma
• Beneficiário: Roberta Andrejew Caetano
• Modalidade de apoio: Bolsas no Brasil - Programa Capacitação - Treinamento Técnico
• Processo FAPESP: 15/13345-1 - Doença de Huntington: envolvimento de Huntingtin no controle do comprometimento celular
• Beneficiário: Talita Glaser
• Modalidade de apoio: Bolsas no Brasil - Pós-Doutorado
• Processo FAPESP: 12/50880-4 - Células-tronco: dos papéis de receptores de cininas e purinas às aplicações terapêuticas
• Beneficiário: Alexander Henning Ulrich
• Modalidade de apoio: Auxílio à Pesquisa - Temático